The Column Group — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatDavid Goeddel· per SEC Form D
Co-investorsNextech InvestVida VenturesSamsara BioCapital
Berkeley, US
Board seatPeter SvennilsonTim KutzkeyLarry Lasky· per SEC Form D · $46.9M raise · filed Oct 2020
Co-investorsColumn
BiotechSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardCraig Parker(Executive Officer, Director)
Board seatDavid GoeddelTim Kutzkey· per SEC Form D · $50M raise · filed Jun 2020
Co-investors5AM Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.